Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of PF-04965842 on Metformin PK in Healthy Participants
NCT03796182Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jan 2019
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of abrocitinib in atopic dermatitis (AD) (2 arms), sponsored by Pfizer. Primary endpoint: Renal Clearance of Metformin. Started Jan 2019; status: completed.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03796182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03796182.